论文部分内容阅读
体外和临床前动物试验数据提示γ干扰素(IFN-γ)和α-肿瘤坏死因子(TNF-α)联合应用可能有加强或协同抗肿瘤作用。作者选择经组织学诊断为实体肿瘤且治疗无效的患者,其标准还包括:(1)卡诺夫斯基性能状态>60%;(2)预期寿命超过3个月;(3)停止化疗、放射治疗、激素治疗、免疫治疗或大手术后至少3周(或停用亚硝基脲和丝裂霉素至少6周);(4)血红蛋白、肾、肝、肺功能和代谢功能适宜;(5)疾病可评价或检测;(6)正式书面同意。排除临床症状明湿的心血管疾病患者和已知出血疾病和癲痫疾病患者。中枢神经系统转移、淋巴系统肺转移,已使用过重组γ-干扰素(rIFN-γ)或重组α肿瘤坏死因子(rTNP-α)的患者不列为研究对象。试验
In vitro and preclinical animal data suggest that the combination of IFN-γ and TNF-α may have enhanced or synergistic anti-tumor effects. The authors selected patients who were histologically diagnosed as solid tumors and who were ineffective in treatment. Their criteria included: (1) Kanovsky’s performance status was >60%; (2) life expectancy exceeded 3 months; and (3) chemotherapy was stopped. At least 3 weeks after radiotherapy, hormone therapy, immunotherapy or major surgery (or at least 6 weeks after cessation of nitrosoureas and mitomycin); (4) Hemoglobin, kidney, liver, lung function and metabolic function are appropriate; ( 5) The disease can be evaluated or tested; (6) Formal written consent. Patients with cardiovascular disease who have clinical symptoms of wetness and those with known bleeding and epilepsy are excluded. Patients with central nervous system metastasis, lymphatic system lung metastasis, and those who have used recombinant IFN-γ or rTNP-α are not included in the study. test